Meeting
2021 Genitourinary Cancers Symposium
A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).
Presenter
Giuseppe Procopio, MD
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03463681
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 326)
DOI
10.1200/JCO.2021.39.6_suppl.326
Abstract #
326
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).
Speaker: Giuseppe Procopio, MD
Speaker: Marcia S. Brose, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).
Speaker: Charlene Mantia, MD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
An observational multicenter French study on unanswered questions in patients with advanced renal cell carcinoma (aRCC) treated with cabozantinib: OCTOPUS.
Speaker: Constance Thibault, MD